Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.
Paul L SwiecickiPin LiEmily BellileChaz StuckenKelly MalloyAndrew ShumanMatthew E SpectorSteven ChinnKeith CasperScott McLeanJeffery MoyerDouglas ChepehaGregory T WolfMark PrinceCarol Rossier BradfordMukesh NyatiAvraham EisbruchFrancis P WordenShruti JollyMichelle MierzwaPublished in: Head & neck (2020)
Among cisplatin ineligible patients, cetuximab treatment engendered poor outcomes. Rates of severe toxicities were on par with platinum-based regimens suggesting that cetuximab is not a benign treatment.